CN105998188A - Pharmaceutical composition, application and preparation method thereof - Google Patents
Pharmaceutical composition, application and preparation method thereof Download PDFInfo
- Publication number
- CN105998188A CN105998188A CN201610548001.9A CN201610548001A CN105998188A CN 105998188 A CN105998188 A CN 105998188A CN 201610548001 A CN201610548001 A CN 201610548001A CN 105998188 A CN105998188 A CN 105998188A
- Authority
- CN
- China
- Prior art keywords
- extracting solution
- pharmaceutical composition
- radix aucklandiae
- sophorae flavescentis
- fructus toosendan
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/285—Aucklandia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/489—Sophora, e.g. necklacepod or mamani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/58—Meliaceae (Chinaberry or Mahogany family), e.g. Azadirachta (neem)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
Abstract
The invention provides a pharmaceutical composition. The pharmaceutical composition is prepared from a radix aucklandiae extracting solution, a lightyellow sophora root extracting solution, a chinaberry seed extracting solution and water, wherein the volume ratio of the radix aucklandiae extracting solution to the pharmaceutical composition is 1:(6-12), the volume ratio of the radix aucklandiae extracting solution to the lightyellow sophora root extracting solution is 1:(0.5-2), and the volume ratio of the radix aucklandiae extracting solution to the chinaberry seed extracting solution is 1:(0.5-2); X g of radix aucklandiae is put into water to be cooked, supernatant is taken, water is added to the scale volume, and X ml of the radix aucklandiae extracting solution is obtained; X g of lightyellow sophora roots are put into water to be cooked, supernatant is taken, water is added to the scale volume, and X ml of the lightyellow sophora root extracting solution is obtained; X g of chinaberry seeds are put into water to be cooked, supernatant is taken, water is added to the scale volume, and X ml of the chinaberry seed extracting solution is obtained. The invention further provides application and a preparation method of the pharmaceutical composition. The pharmaceutical composition can effectively inhibit coccidiosis oocysts of pigs, and the preparation method of the pharmaceutical composition is simple and convenient.
Description
Technical field
The present invention relates to field of biomedicine technology, especially, relate to a kind of pharmaceutical composition,
Application and preparation method thereof.
Background technology
The Radix Aucklandiae is the dry root of the feverfew Radix Aucklandiae, originates in India, is grown in higher mountain region.
Showing according to available data, Aucklandiae alcohol extractive is to 5 kinds of helicobacter pyloris, Fusarium moniliforme；Water
Decoct to paratyphoid fever bacillus and perhaps 10 kinds of funguses such as Lan Shi tinea favosa inhibited.
Fructus Toosendan is the dry mature fruit of Meliaceae plant chinaberry.The main component of chinaberry has Melia azedarach L.
Element, volatile fatty acid, Flos Camelliae Japonicae phenol, resin, tannin etc..Compendium of Material Medica is recorded, bitter
Chinaberry is regulated the flow of vital energy, pain relieving, clearing away damp-heat anthelmintic action.
Radix Sophorae Flavescentis is the root of leguminous plant Radix Sophorae Flavescentis, is Chinese medicine, and its chemical analysis mainly includes raw
Alkaloids, flavone, lignanoid, triterpene saponin, phenolic acid, a small amount of Phenylpropanoid Glycosides class and long-chain fat
Fat acids.There is the effects such as heat clearing and damp drying, antibacterial diuresis, parasite killing, for hematodiarrhoea, have blood in stool,
Eczema, skin pruritus etc..
Pig coccidiosis is by Eimeria and to wait spore to belong to coccidiosis to colonize in swine intestinal epithelium cell and drawn
Rise based on the parasitic disease of piglet digestive pathological changes, show as suffering from diarrhoea, becoming thin and growing is subject to
Resistance.Pig coccidiosis is distribution on global, and Isospora suis causes piglet diarrhea to account for piglet diarrhea
15%-20% in disease, 17, China Henan counties and cities' pig coccidiosis positive rate reaches 94.44%,
Hunan area pig coccidium infection rate is 51.1%.Many employing Baycox preventing and treating pig coccidiosis clinically,
But because the developing immune system of newborn piglet is the most perfect, therefore the infection of parasite cannot be kept out,
And the infection of parasite can destroy the natural cover for defense of body fight cause of disease, easily cause secondary infection.
Long term administration simultaneously makes piglet there is drug resistance and drug residue problem.
Therefore, it is necessary to the medicine of existing anti-pig coccidiosis is further improved, to avoid
Drawbacks described above.
Summary of the invention
Use existing anti-pig coccidiosis medicine to there is drug resistance and medicine for solving above-mentioned piglet
The technical problem of thing residual, the present invention provides a kind of pharmaceutical composition can effectively suppress pig coccidiosis ovum
Capsule has the advantage having no drug resistance with drug residue simultaneously, and the present invention also provides for a kind of described medicine
The application of compositions and the preparation method of a kind of described pharmaceutical composition, have convenient special easily
Point.
The pharmaceutical composition that the present invention provides is carried by Radix Aucklandiae extracting solution, Radix Sophorae Flavescentis extractive liquid, Fructus Toosendan
Taking liquid and water composition, described Radix Aucklandiae extracting solution is 1:1～12 with the volume ratio of described pharmaceutical composition,
Described Radix Aucklandiae extracting solution and described Radix Sophorae Flavescentis extractive liquid volume ratio are 1:0.5～2, and the described Radix Aucklandiae extracts
The volume ratio of liquid and described Fructus Toosendan extracting solution be 1:0.5～: 2；
The X gram of Radix Aucklandiae is put into and is taken supernatant constant volume after boiling in water and prepare the described Radix Aucklandiae of X milliliter and carry
Take liquid；
X gram of Radix Sophorae Flavescentis is put into and is taken supernatant constant volume after boiling in water and prepare the described Radix Sophorae Flavescentis of X milliliter and carry
Take liquid；
X gram of Fructus Toosendan is put into and is taken supernatant constant volume after boiling in water and prepare the described Melia azedarach L. of X milliliter
Sub-extracting solution.
In a kind of preferred embodiment of the pharmaceutical composition of present invention offer, the numerical value of X is more than
20, described in time of boiling more than 1h.
In a kind of preferred embodiment of the pharmaceutical composition of present invention offer, described Radix Sophorae Flavescentis extracts
Liquid is 1:4～4:1 with the volume ratio of described Fructus Toosendan extracting solution.
In a kind of preferred embodiment of the pharmaceutical composition of present invention offer, the described Radix Aucklandiae extracts
The volume ratio of liquid, described Radix Sophorae Flavescentis extractive liquid and described Fructus Toosendan extracting solution is 1:1:1.
In a kind of preferred embodiment of the pharmaceutical composition of present invention offer, the described Radix Aucklandiae extracts
Liquid is 1:6 with the volume ratio of described pharmaceutical composition.
The present invention also provides for the preparation method of a kind of above-mentioned pharmaceutical composition, comprises the following steps:
Step one: weigh the Radix Aucklandiae, Radix Sophorae Flavescentis, Fructus Toosendan are separately added in water, first big fire is boiled,
Then slow fire boils 3～5h, centrifuging and taking supernatant after cooling, and add water constant volume, then autoclaving,
Prepare Radix Aucklandiae extracting solution, Radix Sophorae Flavescentis extractive liquid, Fructus Toosendan extracting solution；
Step 2: the Radix Aucklandiae extracting solution of preparation, Radix Sophorae Flavescentis extractive liquid, Fructus Toosendan in step one are carried
Take liquid and water mixing, prepare described pharmaceutical composition.
The present invention also provides for a kind of above-mentioned pharmaceutical composition medicine at preparation treatment pig coccidiosis
The application of thing.
Compared to prior art, described pharmaceutical composition that the present invention provides, apply and prepare
Method has the advantages that
One, the spore of pig coccidian oocyst can be effectively suppressed by the Radix Aucklandiae, Radix Sophorae Flavescentis and Fructus Toosendan collocation
Change, thus reach to prevent and treat the purpose of pig coccidiosis；
Two, described Radix Aucklandiae extracting solution, described Radix Sophorae Flavescentis extractive liquid and described Fructus Toosendan extracting solution use
Water carries, and preparation method is simple and convenient；
Three, the Radix Aucklandiae, Radix Sophorae Flavescentis and Fructus Toosendan have bacteriostasis so that described pharmaceutical composition exists
The disease while preventing and treating pig coccidiosis caused other microorganisms has therapeutic effect；
Four, described pharmaceutical composition is Chinese medicine extraction liquid, has that drug resistance is little, residual quantity is low
Feature.
Accompanying drawing explanation
For the technical scheme being illustrated more clearly that in the embodiment of the present invention, below will be to embodiment
In description, the required accompanying drawing used is briefly described, it should be apparent that, in describing below
Accompanying drawing is only some embodiments of the present invention, for those of ordinary skill in the art,
On the premise of not paying creative work, it is also possible to obtain other accompanying drawing according to these accompanying drawings,
Wherein:
Fig. 1 is the aspect graph of Sporulated pig coccidian oocyst under normal condition；
Fig. 2 is drug extract one preferred embodiment that provides of the present invention and Sporulated pig coccidiosis
Egg capsule co-cultures the aspect graph of the pig coccidian oocyst after 24h under zygoblast cracking state.
Detailed description of the invention
Below in conjunction with the accompanying drawing in the embodiment of the present invention, to the technical side in the embodiment of the present invention
Case is clearly and completely described, it is clear that described embodiment is only of the present invention
Divide embodiment rather than whole embodiments.Based on the embodiment in the present invention, this area is general
All other embodiments that logical technical staff is obtained under not making creative work premise,
Broadly fall into the scope of protection of the invention.
Unless specifically stated otherwise, non-Sporulated pig coccidian oocyst used in following example and spore
Changing pig coccidian oocyst is pig eimeria tenella.
The present invention provides a kind of pharmaceutical composition, by Radix Aucklandiae extracting solution, Radix Sophorae Flavescentis extractive liquid, Melia azedarach L.
Sub-extracting solution and water composition.Described Radix Aucklandiae extracting solution with the volume ratio of described pharmaceutical composition is
1:6～12, described Radix Aucklandiae extracting solution and described Radix Sophorae Flavescentis extractive liquid volume ratio are 1:0.5～2, described
Radix Aucklandiae extracting solution is 1:0.5～2 with the volume ratio of described Fructus Toosendan extracting solution；Described Radix Sophorae Flavescentis extracts
Liquid is 1:4～4:1 with the volume ratio of described Fructus Toosendan.Preferably, described Radix Aucklandiae extracting solution and institute
The volume ratio stating pharmaceutical composition is 1:6, described Radix Aucklandiae extracting solution, described Radix Sophorae Flavescentis extractive liquid and
The volume ratio of described Fructus Toosendan extracting solution is 1:1:1.
The present invention provides the preparation method of a kind of described pharmaceutical composition, comprises the following steps:
Step S1: weigh the Radix Aucklandiae, Radix Sophorae Flavescentis, Fructus Toosendan are separately added in water, first big fire is boiled,
Then slow fire boils 3～5h, centrifuging and taking supernatant after cooling, and add water constant volume, then autoclaving,
Prepare Radix Aucklandiae extracting solution, Radix Sophorae Flavescentis extractive liquid, Fructus Toosendan extracting solution respectively；
Specifically, weigh the Radix Aucklandiae, Radix Sophorae Flavescentis, each 60g of Fructus Toosendan, be separately added into 500ml aseptic
Distilled water, first big fire boils, and then slow fire boils 4h, and after cooling, 2200r/min is centrifuged 10min,
Take supernatant and be settled to 60ml, after 121 DEG C of autoclaving 20min, prepare the Radix Aucklandiae respectively and extract
Liquid, Radix Sophorae Flavescentis extractive liquid, Fructus Toosendan extracting solution, be stored in 4 DEG C of refrigerators standby.
Step S2: by the Radix Aucklandiae extracting solution of preparation, Radix Sophorae Flavescentis extractive liquid, Fructus Toosendan in step S1
Extracting solution and water mixing, prepare described pharmaceutical composition.
Specifically, by the Radix Aucklandiae extracting solution of preparation, Radix Sophorae Flavescentis extractive liquid, Fructus Toosendan in step S1
Extracting solution mixes with the ratio of volume ratio 1:1:1, adds sterile distilled water mixed diluting, institute
The volume ratio stating Radix Aucklandiae extracting solution and described pharmaceutical composition is 1:6～1:12, it is preferred that described
Radix Aucklandiae extracting solution is 1:6 with the volume ratio of described pharmaceutical composition, described Radix Aucklandiae extracting solution, institute
The volume ratio stating Radix Sophorae Flavescentis extractive liquid and described Fructus Toosendan extracting solution is 1:1:1.
Seeing also Fig. 1 and Fig. 2, Fig. 1 is Sporulated pig coccidian oocyst shape under normal condition
State figure, Fig. 2 is that the present invention provides pharmaceutical composition one preferred embodiment and Sporulated pig coccidiosis ovum
Capsule co-cultures the pig coccidian oocyst aspect graph after 24h under zygoblast cracking state.Pig ball in Fig. 1
In worm's ovum capsule, 4 sub-spore structures are complete, and in Fig. 2, in pig coccidian oocyst, zygoblast cracks,
The most inactivate.
200 μ l are contained the non-Sporulated pig coccidian oocyst of 520 non-Sporulated pig coccidian oocysts
Stock solution is put in 24 porocyte culture plates, takes the different each 200 μ l of culture fluid and is separately added into carefully
Co-culture with non-Sporulated pig coccidian oocyst in born of the same parents' culture plate.Perseverance in the incubator of 26-28 DEG C
Temperature is cultivated, and is cultivating 8h, counted under microscope non-Sporulated pig after 24h, 32h, 48h respectively
Coccidian oocyst Sporulated rate.Using culture fluid of the same race is one group, if 5 times are repeated, and experimental result
Average.
Sporulated rate (%)=(pig coccidiosis Sporulated Oocysts number/pig coccidiosis unsporulated oocysts number) * 100%
A1 group, A2 group, B1 group, B2 group, C1 group, C2 group and matched group are set, its
In,
A1 group culture fluid uses described Radix Aucklandiae extracting solution and described Radix Sophorae Flavescentis extractive liquid with the ratio of 1:1
Example mixes, and adds the dilution of sterile distilled water water and prepares, and described Radix Aucklandiae extracting solution is trained with A1 group
Nutrient solution volume ratio is 1:8；
A2 group culture fluid uses described Radix Aucklandiae extracting solution and described Radix Sophorae Flavescentis extractive liquid with the ratio of 1:1
Example mixes, and adds sterile distilled water dilution and prepares, and described Radix Aucklandiae extracting solution is cultivated with A2 group
Liquid volume ratio is 1:4；
B1 group culture fluid uses described Radix Aucklandiae extracting solution and described Fructus Toosendan extracting solution with 1:1's
Ratio mixes, and adds sterile distilled water dilution and prepares, and described Radix Aucklandiae extracting solution is trained with B1 group
Nutrient solution volume ratio is 1:8；
B2 group culture fluid uses described Radix Aucklandiae extracting solution and described Fructus Toosendan extracting solution with 1:1's
Ratio mixes, and adds sterile distilled water dilution and prepares, and described Radix Aucklandiae extracting solution is trained with B2 group
Nutrient solution volume ratio is 1:4；
C1 group culture fluid uses described Radix Aucklandiae extracting solution, described Radix Sophorae Flavescentis extractive liquid and described Melia azedarach L.
Sub-extracting solution mixes with the ratio of 1:1:1, adds sterile distilled water dilution and prepares, described wood
Fragrant extracting solution is 1:12 with C1 group culture fluid volume ratio；
C2 group culture fluid uses described Radix Aucklandiae extracting solution, described Radix Sophorae Flavescentis extractive liquid and described Melia azedarach L.
Sub-extracting solution mixes with the ratio of 1:1:1, adds sterile distilled water dilution and prepares, described wood
Fragrant extracting solution is 1:6 with C2 group culture fluid volume ratio；
Matched group culture fluid uses 1640 culture medium culturings.
Specific experiment the results are shown in Table 1.
The different culture fluid effect to non-Sporulated pig coccidian oocyst of table 1
Dilution ratio in table 1 refers to the volume ratio of described Radix Aucklandiae extracting solution and culture fluid.
Can be drawn by table 1, compared to matched group, A1 group, A2 group, B1 group, B2 group,
The culture fluid used in C1 group and C2 group can effectively affect non-Sporulated pig coccidian oocyst so that it is
Sporulated rate reduces, and simultaneously along with the increase of concentration, Sporulated rate is gradually lowered.Wherein C2
Group is after 48h, and Sporulated rate is 23.10%.C2 group is the i.e. present invention of culture fluid just provide
By experimental data, the pharmaceutical composition of one preferred embodiment, proves that described pharmaceutical composition can be effective
The Sporulated of suppression pig coccidian oocyst, thus reach to prevent and treat the purpose of pig coccidiosis.
The described pharmaceutical composition of present invention offer, application and preparation method thereof have following useful
Effect:
One, the spore of pig coccidian oocyst can be effectively suppressed by the Radix Aucklandiae, Radix Sophorae Flavescentis and Fructus Toosendan collocation
Change, thus reach to prevent and treat the purpose of pig coccidiosis；
Two, described Radix Aucklandiae extracting solution, described Radix Sophorae Flavescentis extractive liquid and described Fructus Toosendan extracting solution use
Water carries, and preparation method is simple and convenient；
Three, the Radix Aucklandiae, Radix Sophorae Flavescentis and Fructus Toosendan have bacteriostasis so that described pharmaceutical composition exists
The disease while preventing and treating pig coccidiosis caused other microorganisms has therapeutic effect；
Four, described pharmaceutical composition is Chinese medicine extraction liquid, has that drug resistance is little, residual quantity is low
Feature.
The foregoing is only embodiments of the invention, not thereby limit the scope of the claims of the present invention,
Every equivalent structure utilizing description of the invention and accompanying drawing content to be made or equivalence flow process conversion,
Or directly or indirectly it is used in other relevant technical field, the most in like manner it is included in the special of the present invention
In profit protection domain.
Claims (7)
1. a pharmaceutical composition, it is characterised in that by Radix Aucklandiae extracting solution, Radix Sophorae Flavescentis extractive liquid,
Fructus Toosendan extracting solution and water composition, described Radix Aucklandiae extracting solution with the volume ratio of described pharmaceutical composition is
1:6～12, described Radix Aucklandiae extracting solution and described Radix Sophorae Flavescentis extractive liquid volume ratio are 1:0.5～2, the described Radix Aucklandiae
Extracting solution is 1:0.5～2 with the volume ratio of described Fructus Toosendan extracting solution；
The X gram of Radix Aucklandiae put into take after water boils supernatant constant volume prepare the described Radix Aucklandiae of X milliliter extract
Liquid；
X gram of Radix Sophorae Flavescentis put into take after water boils supernatant constant volume prepare the described Radix Sophorae Flavescentis of X milliliter extract
Liquid；
X gram of Fructus Toosendan is put into and is taken supernatant constant volume after boiling in water and prepare the described Fructus Toosendan of X milliliter
Extracting solution.
Pharmaceutical composition the most according to claim 1, it is characterised in that the numerical value of X is big
In 20, described in time of boiling more than 1h.
Pharmaceutical composition the most according to claim 1, it is characterised in that described Radix Sophorae Flavescentis carries
The volume ratio taking liquid and described Fructus Toosendan extracting solution is 1:4～4:1.
Pharmaceutical composition the most according to claim 1, it is characterised in that the described Radix Aucklandiae carries
The volume ratio taking liquid, described Radix Sophorae Flavescentis extractive liquid and described Fructus Toosendan extracting solution is 1:1:1.
Pharmaceutical composition the most according to claim 1, it is characterised in that the described Radix Aucklandiae carries
The volume ratio taking liquid and described pharmaceutical composition is 1:6.
6. a preparation method based on the arbitrary described pharmaceutical composition of Claims 1 to 5, its
It is characterised by, comprises the following steps:
Step one: weigh the Radix Aucklandiae, Radix Sophorae Flavescentis, Fructus Toosendan are separately added in water, first big fire is boiled, so
Rear slow fire boils 3～5h, centrifuging and taking supernatant after cooling, and add water constant volume, then autoclaving, prepares
Radix Aucklandiae extracting solution, Radix Sophorae Flavescentis extractive liquid, Fructus Toosendan extracting solution；
Step 2: the Radix Aucklandiae extracting solution of preparation, Radix Sophorae Flavescentis extractive liquid, Fructus Toosendan in step one are extracted
Liquid and water mixing, prepare described pharmaceutical composition.
7. treat pig ball based on the arbitrary described pharmaceutical composition of Claims 1 to 5 in preparation for one kind
The application of the medicine of parasitosis.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610548001.9A CN105998188A (en) | 2016-07-13 | 2016-07-13 | Pharmaceutical composition, application and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610548001.9A CN105998188A (en) | 2016-07-13 | 2016-07-13 | Pharmaceutical composition, application and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105998188A true CN105998188A (en) | 2016-10-12 |
Family
ID=57108880
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610548001.9A Pending CN105998188A (en) | 2016-07-13 | 2016-07-13 | Pharmaceutical composition, application and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105998188A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115804425A (en) * | 2022-12-07 | 2023-03-17 | 长沙市惠瑞生物科技有限公司 | Feed composition for killing pig intestinal parasitic diseases and preparation method thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101234161A (en) * | 2007-09-29 | 2008-08-06 | 孙承宽 | Production method of liquid for eliminating poultry plague |
| CN103071009A (en) * | 2013-01-14 | 2013-05-01 | 成都科创佳思科技有限公司 | Chinese patent drug for treatment of enterobiasis in external and internal administration |
| CN103830470A (en) * | 2012-11-21 | 2014-06-04 | 青岛康地恩动物药业有限公司 | Traditional Chinese medicine for treatment of diarrhea of pigs |
| CN103990052A (en) * | 2014-05-26 | 2014-08-20 | 湖州天健兽药有限公司 | Traditional Chinese veterinary medicine for invigorating stomach of piglets |
-
2016
- 2016-07-13 CN CN201610548001.9A patent/CN105998188A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101234161A (en) * | 2007-09-29 | 2008-08-06 | 孙承宽 | Production method of liquid for eliminating poultry plague |
| CN103830470A (en) * | 2012-11-21 | 2014-06-04 | 青岛康地恩动物药业有限公司 | Traditional Chinese medicine for treatment of diarrhea of pigs |
| CN103071009A (en) * | 2013-01-14 | 2013-05-01 | 成都科创佳思科技有限公司 | Chinese patent drug for treatment of enterobiasis in external and internal administration |
| CN103990052A (en) * | 2014-05-26 | 2014-08-20 | 湖州天健兽药有限公司 | Traditional Chinese veterinary medicine for invigorating stomach of piglets |
Non-Patent Citations (2)
| Title |
|---|
| 张国增: "《中兽医防治禽病》", 28 February 2013, 中国农业出版社 * |
| 李世全 主编: "《秦岭巴山天然药物志》", 31 May 1987, 山西科学技术出版社 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115804425A (en) * | 2022-12-07 | 2023-03-17 | 长沙市惠瑞生物科技有限公司 | Feed composition for killing pig intestinal parasitic diseases and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Shah et al. | Ethnomedicinal uses of plants for the treatment of malaria in Soon Valley, Khushab, Pakistan | |
| Pio et al. | Traditional knowledge and uses of medicinal plants by the inhabitants of the islands of the São Francisco river, Brazil and preliminary analysis of Rhaphiodon echinus (Lamiaceae) | |
| Balogun et al. | Gongronema latifolium: A phytochemical, nutritional and pharmacological review | |
| Fatima et al. | Phytomedicinal value of Moringa oleifera with special reference to antiparasitics. | |
| Saab et al. | Phytochemical analysis and potential natural compounds against SARS-CoV-2/COVID-19 in essential oils derived from medicinal plants originating from Lebanon. An information note | |
| Al-Mashhadani et al. | Effect of supplementing different levels of chamomile oil on broiler performance and some physiological traits | |
| Shi et al. | The genus Orobanche as food and medicine: An ethnopharmacological review | |
| Mahomoodally et al. | A quantitative ethnopharmacological documentation of natural pharmacological agents used by pediatric patients in Mauritius | |
| Goyal et al. | Trachyspermum ammi: A review on traditional and modern pharmacological aspects | |
| CN106176501A (en) | A kind of baby massage oil of gentleness | |
| CN102078313A (en) | High-efficiency, low-toxicity and safe plant source acaricidal medicament and preparation method thereof | |
| Islomova et al. | Ethnobotany, medicinal utilization and analysis of biogenic elements and flavonoids of Apium graveolens and Tussilago farfara from Uzbekistan | |
| CN101530497B (en) | Extract and composition of rutaceae zanthoxylum peel, preparing method and application thereof | |
| Ebeye et al. | The histological effect of Cnidoscolus aconitifolius aqueous leaf extracts on the archetecture of the ovary, testis and sperm cells of adult wistar rats | |
| CN105410569A (en) | Preparation method of mulberry drink with protective effect on alcoholic liver injury | |
| CN105998188A (en) | Pharmaceutical composition, application and preparation method thereof | |
| CN108464968B (en) | Anti-inflammatory cream for infants and preparation method thereof | |
| Gupta et al. | Himalayan toxic plants of defense importance | |
| CN104435595A (en) | Medicine for treating white spot disease of turtle | |
| Dardona | Literature Review: Punica granatum (pomegranate) with an emphasis on its anti-parasitic activity | |
| Nirala et al. | Medicinal plants and its activity against helminth: A review | |
| CN105935392A (en) | Traditional Chinese medicine composition for treating hyperlipidemia, preparation method and applications thereof | |
| Nunes et al. | Antiulcerogenic activity of ethanol extract of the bark from Terminalia catappa in gastric ulcer model induced by ethanol in Rattus norvegicus | |
| CN102614349B (en) | Traditional Chinese medical composition for prevention and treatment of A type clostridiosis welchii, extract, preparation and preparation method and application | |
| CN100486600C (en) | Application of spanishneedles herb flavonid in preparing medicine for preventing and treating liver fibrosis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20161012 |